Primary Hepatocellular Carcinoma Clinical Trial
Official title:
Clinical Study on the Safety and Efficacy of Mixed-activated Killer Immune Cells in the Treatment of Primary Hepatocellular Carcinoma
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral blood mononuclear cells were obtained and then the MAK(Mixed-activated Killer) cells were injected, and then the safety and efficacy were observed.
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral venous blood was collected twice (50-60ml/time, 2 times, 1 week apart) from each patient. Peripheral blood mononuclear cells were separated, induced, expanded, and cultured in vitro for a total of 1 week to obtain physiological conditions Immune cell populations with tumor-killing activity (mainly MAK immune cells mainly CD3-CD16 + CD56 + and CD3 + CD56 +), and then the MAK(Mixed-activated Killer) cells were injected intravenously for three days. Observe that the patient received cell therapy 24h, The safety and efficacy of 1 month, 2 months, and 3 months, and monitoring of adverse reactions. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00966251 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03614546 -
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
|
N/A | |
| Not yet recruiting |
NCT03672305 -
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
|
Early Phase 1 | |
| Not yet recruiting |
NCT06124001 -
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02956772 -
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
|
Phase 2 | |
| Active, not recruiting |
NCT01563484 -
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05872841 -
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
|
Phase 2 | |
| Completed |
NCT01828762 -
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
|
N/A |